VESELÝ, Branislav, Michal DUFEK, Vojtěch THON, M. BROZMAN, S. KIRALOVA, T. HALASZOVA, Eva KORIŤÁKOVÁ and Ivan REKTOR. Interleukin 6 and complement serum level study in Parkinson's disease. Journal of Neural Transmission. WIEN: SPRINGER WIEN, 2018, vol. 125, No 5, p. 875-881. ISSN 0300-9564. Available from: https://dx.doi.org/10.1007/s00702-018-1857-5.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Interleukin 6 and complement serum level study in Parkinson's disease
Authors VESELÝ, Branislav (703 Slovakia, belonging to the institution), Michal DUFEK (203 Czech Republic, belonging to the institution), Vojtěch THON (203 Czech Republic, belonging to the institution), M. BROZMAN (703 Slovakia), S. KIRALOVA (703 Slovakia), T. HALASZOVA (703 Slovakia), Eva KORIŤÁKOVÁ (203 Czech Republic, belonging to the institution) and Ivan REKTOR (203 Czech Republic, guarantor, belonging to the institution).
Edition Journal of Neural Transmission, WIEN, SPRINGER WIEN, 2018, 0300-9564.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30103 Neurosciences
Country of publisher Austria
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.903
RIV identification code RIV/00216224:14740/18:00103549
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1007/s00702-018-1857-5
UT WoS 000430583400010
Keywords in English Complement; Interleukin 6; Parkinson's disease
Tags 14110114, 14110127, 14119612, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 13/3/2019 13:37.
Abstract
The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.
Links
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 13/7/2024 12:42